Disclosures for "Real-World Experience with Long-term Lecanemab Treatment: A Retrospective Chart Review in Early Alzheimer’s Disease "
-
Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Iqvia. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acumen. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weisman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for eisai. Dr. Weisman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lantheus. Dr. Weisman has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Eisai. Dr. Weisman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lilly. The institution of Dr. Weisman has received research support from Eisai. The institution of Dr. Weisman has received research support from Biogen. The institution of Dr. Weisman has received research support from Roche. The institution of Dr. Weisman has received research support from Vivoryon. The institution of Dr. Weisman has received research support from Lilly. The institution of Dr. Weisman has received research support from Acumen. The institution of Dr. Weisman has received research support from Cerevel. The institution of Dr. Weisman has received research support from Sage. The institution of Dr. Weisman has received research support from Annovis. The institution of Dr. Weisman has received research support from Serono. The institution of Dr. Weisman has received research support from Acadia. The institution of Dr. Weisman has received research support from Alnylam. The institution of Dr. Weisman has received research support from Ventus. The institution of Dr. Weisman has received research support from Cognition. Dr. Weisman has received intellectual property interests from a discovery or technology relating to health care. Dr. Weisman has received intellectual property interests from a discovery or technology relating to health care. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Peripheral and Central Nervous System Drugs Advisory Committee with FDA.
-
Miss Nimma has nothing to disclose.
-
Miss Lutz has nothing to disclose.
-
Ms. Scott has nothing to disclose.
-
Ms. Mosley has nothing to disclose.
-
Ms. Kodsi has nothing to disclose.
-
Dr. Yellin has nothing to disclose.